ProfileGDS5678 / 1417508_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 88% 88% 88% 89% 90% 89% 88% 89% 89% 90% 89% 91% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.9990789
GSM967853U87-EV human glioblastoma xenograft - Control 26.9545688
GSM967854U87-EV human glioblastoma xenograft - Control 36.957988
GSM967855U87-EV human glioblastoma xenograft - Control 46.962788
GSM967856U87-EV human glioblastoma xenograft - Control 57.0728989
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.9217590
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.892189
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8466388
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.9076989
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1445789
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.1929290
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0636889
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.3468291
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.1869590